Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma (OESIRI)

• ClinicalTrials.gov Identifier: NCT03719924
• Recruitment Status: Recruiting
• First Posted: October 25, 2018
• Last Update Posted: March 14, 2019
• Sponsor: Federation Francophone de Cancerologie Digestive
• Collaborator: Shire
• Information provided by (Responsible Party): Federation Francophone de Cancerologie Digestive

Study Description

Brief Summary:

The aim of our study is to evaluate the efficacy and safety of NALIRI plus 5FU versus paclitaxel as a second-line therapy in patients with locally advanced or metastatic ESCC who had failed to cisplatin- or oxaliplatin-based first-line chemotherapy.

The hypotheses are as follows:

H0: the percentage of patients alive at 9 months of 40% is not useful. H1: the percentage of patients alive at 9 months of 60% is expected.

Condition or disease	Intervention/treatment	Phase
Squamous Cell Carcinoma	Drug: Onivyde; Drug: Paclitaxel	Phase 2

Detailed Description:

Principal objective:

• To evaluate the survival of patients at 9 months

Secondary objectives:

• Progression-free survival (PFS) (clinical and/or radiological)
• Overall survival (OS)
• Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and the centralised review committee)
• Toxicity (NCI CTC 4.0)
• Quality of life (QLQ-C30 and OES18 questionnaires of the EORTC)

Arm A (experimental arm): Nal IRI plus LV5-FU (D1=D28) Nal-IRI: 80 mg/m² intravenous over 90 minutes Followed by intravenous folinic acid 400 mg/m² over 30 minutes or L-folinic acid: 200 mg/m² over 30 minutes And then 5-FU 2,400 mg/m² over 46 hours on D1 to D14 Patients known to be homozygous for the UGT1A1*28 allele who are to be randomized to the Nal-IRI/5-FU Arm receive the first cycle of therapy with a reduced dose of Nal IRI of 60 mg/m2. If the patient does not present any toxicity related to the medicinal product after the first administration of Nal IRI, the dose can be increased to 80 mg/m2 starting with cycle 2.

Arm B (control arm): PACLITAXEL (D1=D28) Paclitaxel: 80 mg/m² at D1, D8 and D15

Patients will be randomized in a 1:1 ratio using the minimisation technique. Randomisation will be stratified based on the following factors:

• Centre
• WHO performance status: 0/1 versus 2

An analysis of circulating tumour DNA (using genetic mutations, in particular, TP53, and DNA methylation analyses) will be performed before the 1st cycle of treatment and at D28, in order to look for factors predictive of response to treatment (decrease in unbound DNA).

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 106 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment

Intervention Model Description

All initial characteristics will be described in the overall population and by treatment arm. Evaluation criteria related to efficacy and safety will be described by treatment arm. Initial characteristics of best response and toxicities will be evaluated using usual statistics: for quantitative variables: mean, standard deviation, median, interquartile interval and range and for qualitative variables: frequencies and percentages.

For the primary evaluation end point, a one-sided 95% confidence interval (CI) will be calculated in the experimental arm.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA A Multi-centre, Randomized, Non-comparative Phase II Study
• Actual Study Start Date: March 7, 2019
• Estimated Primary Completion Date: July 15, 2021
• Estimated Study Completion Date: April 15, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: arm A: ONIVYDE; ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours	Drug: Onivyde; onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.; Other Name: no other intervention name to add
Active Comparator: Arm B: TAXOL; TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15	Drug: Paclitaxel; Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15; Other Name: no other intervention name to add

Outcome Measures

Primary Outcome Measures :

1. survival at 9 months [ Time Frame: 9 months ]
   The principal objective is to evaluate survival at 9 months in patients presenting with metastatic oesophageal squamous cell carcinoma (OSC) treated with Nal-IRI/LV5-FU or with paclitaxel.

Secondary Outcome Measures :

1. Progression-free survival [ Time Frame: 5 years ]
   Clinical Progression-free survival and/or radiological Progression free survival will be evaluated
2. Overall survival (OS) [ Time Frame: 1 year ]
   evaluate the overall survival
3. Best response rate during treatment [ Time Frame: 6 months ]
   Best response rate during treatment according to RECIST 1.1 criteria (according to the investigator and with centralised review)
4. Toxicity (NCI-CTC v4) [ Time Frame: 6 months ]
   all observed toxicities, graded according to NCI-CTC v4 and the SAE
5. Quality of life (questionnaires) [ Time Frame: 6 months ]
   Quality of life (QLQ-C30 questionnaires of EORTC) and OES18 questionnaires of EORTC

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Histologically proven metastatic oesophageal squamous cell carcinoma
• Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients presenting with resectable disease treated with surgery or neoadjuvant or adjuvant chemotherapy with oxaliplatin or cisplatin (with or without radiotherapy) can be included if a recurrence has occurred less than 6 months after the end of treatment
• Age ≥ 18 years
• Unresectable disease, measurable or not, according to RECIST 1.1 criteria
• WHO performance status ≤ 2
• Neutrophils ≥ 1500/mm3 (without use of haematopoietic growth factors), platelets ≥ 100 000/mm3, haemoglobin ≥ 9 g/dl (blood transfusions are authorised for patients with a haemoglobin less than 9 g/dl)
• Total bilirubin ≤ 2 x ULN (biliary drainage is authorised in case of a biliary obstruction); albumin ≥ 25 g/L; AST ≤ 2.5 x ULN, and ALT ≤ 2.5 x ULN (≤ 5 x ULN in case of hepatic metastases)
• Creatinine clearance ≥ 50 ml/min according to MDRD formula
• A normal ECG or ECG with no clinically significant findings
• Patient able to understand and to sign the informed consent form (or who has a legal guardian able to do so for him/him)
• Women of childbearing potential must have a negative pregnancy blood or urine test within 7 days prior to inclusion
• Women of childbearing potential, as well as men (who have sexual relations with women of childbearing potential) must agree to use an effective method of contraception throughout this study and during the 6 months following administration of the last dose of the study medicinal product
• Patient who is a beneficiary of the Social security system
• Patient for whom regular follow-up is possible.

Exclusion Criteria:

• Known brain or bone metastases
• Clinically significant gastrointestinal disorders, including hepatic, haemorrhagic, inflammatory, obstructive disorders or diarrhoea > grade 1
• History of chronic inflammatory bowel disease
• Gilbert's syndrome
• Interstitial lung disease
• Treatment with St John's Wort
• Medical history of Whipple procedure
• Body mass index < 18.5 kg/m2
• Combination with sorivudine and others analogues as brivudine (irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase)
• History of progressive cancer or in remission of less than 3 years duration (patients who present with a cancer in situ or basal cell or squamous cell skin cancer during the last 3 years are eligible).
• Severe arterial thromboembolic events (myocardial infarction, unstable angina, stroke) less than 3 months before inclusion
• NYHA class III or IV congestive heart failure, ventricular arrhythmia or uncontrolled blood pressure
• Significant neuropathy ≥ grade 2 according to NCI CTCAE criteria (National Cancer Institute Common Terminology Criteria for Adverse Events) v.4.0.
• Known hypersensitivity or allergy to a component of the medicinal products used in the study.
• Known DPD deficiency

Contacts and Locations

Contacts

Contact: DAVID TOUGERON; 05.49.44.37.51 ext 42109; David.TOUGERON@chu-poitiers.fr

Locations

France

Ch Perpignan; Recruiting

Perpignan, France

Chu de Poitiers; Not yet recruiting

Poitiers, France

Contact: DAVID TOUGERON, PR

Sponsors and Collaborators

Federation Francophone de Cancerologie Digestive

Shire

More Information

• Responsible Party: Federation Francophone de Cancerologie Digestive
• ClinicalTrials.gov Identifier: NCT03719924
• Other Study ID Numbers: PRODIGE 62 - OESIRI
• First Posted: October 25, 2018
• Last Update Posted: March 14, 2019
• Last Verified: October 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Federation Francophone de Cancerologie Digestive:

ESCC NAL-IRI

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Esophageal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases; Paclitaxel; Albumin-Bound Paclitaxel; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action